The expression of brown fat associated proteins in colorectal cancer and the relationship of uncoupling protein 1 with prognosis by Alnabulsi, Abdo et al.
1 
 
The expression of brown fat associated proteins in colorectal cancer and the 
relationship of uncoupling protein 1 with prognosis 
Abdo Alnabulsi1,2, Beatriz Cash2, Yehfang Hu3, Linda Silina4, Ayham Alnabulsi2,  
Graeme I Murray1 
 
1Pathology, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, 
Aberdeen, AB25, 2ZD, UK, 2Vertebrate Antibodies, Zoology Building, Tillydrone Avenue, 
Aberdeen, AB24 2TZ, UK, 3Scottish Fish Immunology Research Centre, School of 
Biological Sciences, University of Aberdeen, Aberdeen, AB24 2TZ, UK. 4School of 
Biological Sciences, University of Aberdeen, Aberdeen, AB24 2TZ, UK. 
 
Address correspondence to: Professor Graeme I Murray 
Email g.i.murray@abdn.ac.uk 
Phone: +44(0)1224 553794 
Fax: +44(0)1224 663002 
 
Number of figure: 2 
Number of tables: 4 
Words count: 3959  
 
Running title: UCP1 and prognosis in colorectal cancer. 
Keywords: biomarker, colorectal cancer, mitochondria, prognosis, uncoupling protein 1. 
Article category: Tumour Markers and Signatures. 
 
Abbreviations: AKT: AKT serine/threonine kinase 1; ATP: adenosine triphosphate; 
BLAST: basic local alignment search; CI: confidence interval; CIDEA: cell-death-inducing 
DNA fragment factor 45-like effector A; ELISA: enzyme-linked immunosorbent assay; 
ELOVL3: elongation of very long fatty acids 3; ELOVL5: elongation of very long fatty acids 
5; EMVI: extramural venous invasion; MLH1: mutL homolog 1; MMR: mismatch repair 
protein; MSH2: mutS homolog 2; UCP1: uncoupling protein 1. 
 
Novelty and Impact:  
This is the first study to examine brown fat-associated proteins CIDEA, ELOVL3, 
ELOVL5 and UCP1 in colorectal cancer. Monoclonal antibodies towards these proteins were 
produced using specific peptide immunogens which had been identified using a range of 
bioinformatics tools. CIDEA, ELOVL3, ELOVL5 and UCP1 were evaluated in well-
characterised discovery and validation cohorts of colorectal cancer.  The expression of UCP1 
emerged as a biomarker strongly and independently associated with survival in colorectal 
cancer.  
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Abstract 
Colorectal carcinoma is one of the most common types of malignancy and a leading 
cause of cancer related death.  The aberrant expression of a brown fat-like phenotype in 
cancer cells has been previously implicated in tumour growth. Therefore, the expression of 
brown fat-associated proteins in colorectal cancer could be associated with tumour prognosis. 
Monoclonal antibodies to brown fat-associated proteins CIDEA, ELOVL3, ELOVL5, 
and UCP1 were developed.  The antibodies were used to profile the expression of protein 
targets by immunohistochemistry in a discovery cohort comprising 50 normal colonic 
mucosa samples and 274 primary colorectal cancers and a validation cohort comprising 549 
colorectal cancers.   
Immunostaining for UCP1 was observed in the majority of colorectal tumours while 
no immunostaining was observed in normal colonic mucosa (p<0.001).  The expression of 
UCP1 was significantly associated with better overall survival in both the discovery cohort 
(HR=0.615, 95%CI=0.416-0.909, χ2 =6.119, p=0.013) and the validation cohort (HR=0.629, 
95%CI=0.480-0.825, χ2=11.558, p=0.001).  Furthermore, UCP1 was independently 
prognostic in multivariate analysis (p=0.004).  
This study has identified the brown fat-like phenotype as a novel pathway associated 
with survival in colorectal cancer.  The expression of UCP1 was identified as a significant 
prognostic biomarker for colorectal cancer.   
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Introduction 
 Colorectal cancer is a common malignancy with a poor mortality rate and a negative 
impact on the quality of life of survivors.1,2  The incidence rate of colorectal cancer is 
relatively high in the developed world and such figures are expected to continue rising in the 
future.3,4  Although the mortality rate of colorectal cancer has been declining as result of the 
ongoing developments in clinical practice, the average five-year survival rate remains 
relatively poor at around 55%.2  To improve our understanding of colorectal tumourigenesis 
and provide a platform for innovative improvements in the outcome from colorectal cancer, 
there is still a need for further molecular characterisation of colorectal cancer.5,6 
 Adipose tissue is a connective tissue that is mainly populated by adipocyte and pre-
adipocyte cells.  The vast majority of fat tissue in adult humans is classified as white fat and 
is involved in many functions such as energy storage, metabolism, insulin sensitivity and 
inflammation.7  The other type of fat tissue is known as brown fat which is composed of 
brown adipocytes that are rich in mitochondrial content thus giving deposits of brown fat 
their characteristic brownish colour.7  Brown fat is limited to very small depots in the 
cervical, supraclavicular, axillary and paravertebral areas in adult humans.8  Brown fat has 
been primarily implicated in energy expenditure and in diseases such diabetes and obesity.7 
 The brown fat phenotype is primarily characterised by the expression of uncoupling 
protein 1 (UCP1).  The expression of UCP1 causes a proton leak in the mitochondrial 
respiratory chain leading to energy dissipation as heat rather than in the form of adenosine 
triphosphate (ATP), therefore; it is mainly associated with energy expenditure and 
metabolism.9  Other key proteins associated with brown fat phenotype include; cell-death-
inducing DNA fragment factor 45-like effector A (CIDEA) and elongation of very long fatty 
acids 3 (ELOVL3).10,11  The main biological function of CIDEA has not been fully defined 
but has been mainly implicated in lipid and energy metabolism.12  ELOVL3 elongates 
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saturated and monounsaturated fatty acids and is involved in triglyceride formation in brown 
adipocytes.13  Whereas, ELOVL5 is a novel family member of long fatty chain elongases and 
is involved in the elongation of polyunsaturated fatty acids such as arachidonic acid and 
docosahexaenoic acid.14  
 There has been limited research on the expression of brown fat-phenotype in 
neoplasms of epithelial origin.  The manifestation of brown fat phenotype, characterised by 
UCP1 expression, was detected by immunohistochemistry in the epithelial compartment of 
prostate cancer tissue, and in vitro analysis showed this phenotype was associated with 
tumour growth and progression.15  The expression of UCP1 was also detected in a 
subpopulation of cancer stem cells in the early stages of breast cancer xenografts.16   
 The potential expression of the brown fat phenotype in colorectal carcinoma is 
unknown and more importantly, the relationship between the expression of this phenotype 
and survival among other clinico-pathological parameters has not been investigated.  
Therefore, the aim of this study was to characterise the expression of key brown fat-
associated proteins and to evaluate their clinical relevance in colorectal cancer. 
Using monoclonal antibodies, we have developed to brown fat-associated proteins, we 
have evaluated the expression of CIDEA, ELOVL3, ELOVL5 and UCP1 on tissue 
microarrays containing well-characterised cohorts of primary colorectal cancers.  The use of 
tissue microarrays is a well-established approach to high throughput immunohistochemistry-
based biomarker studies.  The expression profile of each protein was established by light 
microscopy using a semi-quantitative scoring system.17  The prognostic significance of each 
protein was determined by assessing the relationship between their expression in tumours and 
overall survival.   
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Materials and methods 
Monoclonal antibody development 
 Monoclonal antibodies to CIDEA, ELOVL3, ELOVL5 and UCP1 were developed 
using short synthetic peptides.17  To facilitate the identification of specific immunogenic 
peptides (8-12 amino acids in length) a range of bioinformatics tools were used 
(Supplementary Table S1).  This comprised homology and structural analysis of each protein 
and bioinformatics prediction of each immunogen peptide.  Homology analysis was mainly 
performed by aligning the amino acids sequence of each protein with their family members, 
thereby, selecting specific peptides from regions with high amino acids diversity 
(Supplementary Figure S1).  The secondary and tertiary structures of each protein were 
predicted using online bioinformatics tools and then analysed to identify accessible regions 
(Supplementary Figures S2, S3 and S4).  Finally, after selecting a candidate peptide 
sequence, its specificity to the target of interest was evaluated by sequence comparison 
against UniProtKB 'Complete human proteome database' using basic local alignment search 
tool (BLAST). 
 The amino acid sequences of peptides used to generate the antibodies and their 
location on each protein are specified in Supplementary Table S2.  All peptides (Almac 
Sciences Ltd, Edinburgh, UK) were conjugated to ovalbumin for immunisations and to 
bovine serum albumin for the enzyme-linked immunosorbent assay (ELISA) screenings.18  
The immunisation via the subcutaneous route, the production of hybridomas and the ELISA 
screenings were carried out as previously described.19-21 
 
Monoclonal antibody characterisation 
 To evaluate the specificity of monoclonal antibodies, immunoblotting was performed 
using whole cell lysate which is made of human embryonic kidney cells-HEK 293, 
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overexpressing the relevant protein as a positive control and lysates from HEK 293 cells 
containing empty vector as a negative control (Novus Biologicals, Oxfordshire, UK and 
OriGene Technologies Rockville, USA).  To overexpress each protein, HEK293 cells had 
been transiently transfected using the full length reading frame cDNA plasmid of the 
corresponding gene (Novus Biologicals, Oxfordshire, UK and OriGene Technologies 
Rockville, USA). The immunoblotting was carried out as previously described.22   
The initial immunohistochemical evaluation of each of the antibodies and their tissue 
specificity was performed using a multi-tissue microarray which was designed to include a 
wide range of normal tissue and tumour types (Supplementary Table S3).   
 
Colorectal cancer patient cohorts 
 Two well-characterised patient cohorts were used for profiling each brown fat 
associated protein in colorectal cancer.  The patient cohorts were retrospectively acquired 
from the Grampian Biorepository (www.biorepository.nhsgrampian.org) and randomly 
assigned to discovery and validation sets at a ratio of 1:2.  Both groups of patients had 
undergone surgery with curative intent for primary colorectal cancers between 1994 and 
2011, at Aberdeen Royal Infirmary-NHS Grampian (Aberdeen, UK).  Only patients with 
UICC stage I, stage II or stage III were included in the study while patients with histological 
evidence of distant metastasis were excluded. Patients who had received neoadjuvant 
chemotherapy and/or radiotherapy were also excluded. All tissue samples were processed 
following a standard protocol.  Further details on the histopathological processing of tissue 
specimens are described in Supplementary Materials and Methods S1. 
Tissue samples from 274 patients were selected as the discovery cohort and 549 
patients were selected as the validation cohort.  The clinico-pathological characteristics of 
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patients in the discovery and validation cohorts were comparable descriptively and 
statistically, except for mismatch repair protein (MMR) status (Supplementary Table S4). 
 Survival data on a 6-monthly basis was updated from the NHS Grampian electronic 
patient management system.  Overall survival time was defined as the period from 28 days 
after the date of surgery to the date of death from any cause.  At the date of final censoring of 
patient outcome data (March 2012), no patients had been lost to follow-up and patients who 
were still alive were censored.  The clinico-pathological characteristics and their association 
with survival for each patient cohort are described in Table 1. 
 For the discovery cohort, there had been 112 (40.9%) deaths, the median survival was 
109 months (95% CI=84-134 months) and the median follow-up time, calculated by the 
“reverse Kaplan-Meier” method, was 61 months (95% CI=44-78 months).  For the validation 
cohort, there had been 229 (41.7%) deaths, the median survival was 93 months (95% CI=74-
112 months) and the median follow-up time was 70 months (95% CI=66-74 months).   
 The Royal College of Pathologists UK guidelines, including guidance from version 5 
of the tumour, node, metastasis staging system, were followed for the histopathological 
reporting of resection specimens of colorectal cancer.23  
 
Colorectal cancer tissue microarrays 
 A colorectal cancer tissue microarray was constructed from the discovery cohort 
consisting of 274 primary colorectal tumours and 50 normal colon mucosal samples (acquired 
from at least 10 cm in distance from the tumour).  Similarly, a tissue microarray was 
constructed consisting of 549 primary tumour samples from the validation cohort.  For each 
tissue sample, two representative 1 mm cores were obtained from the corresponding formalin 
fixed, paraffin embedded block to construct the tissue microarrays.21,22,24   
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Immunohistochemistry 
Monoclonal antibody characterisation using multi-tissue microarray 
 Immunohistochemistry was performed using a Dako autostainer (Dako universal 
staining system, Dako/Agilent Technologies LDA UK Limited, Cheadle, UK).21,22  The 
immunohistochemistry method is detailed in Supplementary Materials and Methods S1.  
Antibody diluent (Dako) was used in place of the primary monoclonal antibody as a negative 
control.  For each antibody one slide was tested without antigen retrieval and one slide was 
tested with antigen retrieval.  Antigen retrieval was performed by microwaving the tissue 
slides for 20 minutes while fully immersed in 10mM citrate buffer pH 6.0.  The 
immunostaining results were assessed using light microscopy by AA and GIM.  The 
immunostaining profile for each antibody (i.e. the subcellular localisation, the tissue 
expression profile and the presence of any background staining) was assessed and interpreted 
in the context of existing knowledge for the tissue specific expression of each gene. The 
specificity of UCP1 was additionally assessed using hibernoma (brown fat tumour) samples. 
 
Protein characterisation using colorectal cancer tissue microarrays 
 The immunostaining of the colorectal cancer tissue microarrays was performed for 
each antibody as described above.  An appropriate positive control tissue (CIDEA, ELOVL3 
and ELOVL5-liver, UCP1-pancreas and hibernoma) was included for each antibody. The 
negative control for each antibody was antibody diluent in place of the primary monoclonal 
antibody. The immunostaining results were evaluated under light microscopy using an 
established semi-quantitative scoring system that is based on the intensity of immunostaining 
(Supplementary Figure S5).22,24-26  Positive staining was regarded as any staining of tumour 
cells while negative staining was considered as an absence of tumour cell staining as 
previously described. 22,24-26 The scoring was conducted independently by two observers (AA 
9 
 
and GIM) who were unaware of the outcome.  Any discrepancies in the scores were resolved 
through simultaneous re-evaluation of the cores by both observers. Cases were recorded as 
missing if the evaluation of immunostaining was not possible due to the tissue cores being 
damaged/folded during the staining process precluding immunohistochemical assessment or 
there were no tumour cells present in the relevant cores. 
 
Assessment of mismatch repair protein (MMR) status 
 The assessment of MLH1 and MSH2 proteins by immunohistochemistry was used to 
determine whether tumours were either MMR protein proficient or MMR protein deficient.21 
 
Data analysis and statistics 
 The immunostaining scores of the colorectal cancer tissue microarrays were recorded 
in an Excel 2013 spreadsheet before being analysed using IBM SPSS version 24 for 
Windows 7 (IBM, Portsmouth, UK).  Statistical tests that were used to analyse the data 
included Mann-Whitney U test, chi-squared test, Kaplan-Meier survival analysis, log-rank 
test and Cox regression analysis for the calculation of hazard ratios and 95% CIs.  The 
clinico-pathological characteristics of both cohorts were compared descriptively and by chi-
squared tests.  Univariate survival analysis was performed for both the discovery and 
validation cohorts.  For the validation cohort multivariate Cox regression analysis 
(“ENTER” method) was also used to evaluate the prognostic significance of each protein in 
relation to established prognostic variables: age, tumour differentiation, T category, N 
category and extramural venous invasion (EMVI).  Patients were also dichotomised into 
clinically relevant low-risk and high-risk stratification groups based on T category, N 
category, tumour differentiation and EMVI: low-risk group: (pT1-pT3, EMVI absent (V0) 
and well/moderately differentiated tumour (G1, G2)) and pN0 vs high-risk group: (pT4 or 
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EMVI present (V1) or poorly differentiated tumour (G3)) and pN0 or any lymph node 
positive tumour (pN1 or pN2).27  A probability value of p≤0.05 was regarded as statistically 
significant.  Additional details of the data analysis are provided in Supplementary Materials 
and Methods S1. 
 
Ethics 
Ethical approval for the use of colorectal and other tissue samples was given by the 
Grampian Biorepository scientific access group committee (Tissue request No.0002).  The 
use of tissue samples included in the tissue microarrays did not require written consent from 
patients. 
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Results 
Monoclonal antibody development  
 During the hybridoma production, ELISA screenings were used to evaluate the 
specificity of antibodies to immunogen peptides used in immunisation.  Further evaluation of 
the specificity of each antibody towards the relevant protein was performed by 
immunoblotting.  A single band at the expected molecular weight of the relevant protein was 
observed in the corresponding overexpression lysate while no band was detected in the 
negative control (Supplementary Figure S6).   
 The immunoreactivity and tissue specificity of antibodies on a multi-tissue microarray 
was also evaluated by immunohistochemistry.  Neat culture supernatant was used for each 
antibody except for ELOVL3 (1:10 dilution) and antigen retrieval was required for each 
antibody.  CIDEA was mainly expressed in normal colon and normal breast tissue.  ELOVL3 
enzyme was strongly expressed in normal skin, breast, colon, liver, while ELOVL5 was 
widely expressed.  Immunoreactivity for UCP1 was observed in endocrine pancreas and in 
hibernoma tissue (Supplementary Figure S7).   
 
Immunostaining profile of proteins in colorectal cancer  
 In the discovery cohort, CIDEA, ELVOL3 and ELVOL5 each showed 
immunoreactivity in normal colonic epithelium and primary colorectal tumours.  There was 
no immunoreactivity for UCP1 in normal colonic mucosa while the majority of primary 
tumours showed immunostaining for UCP1.  Furthermore, the expression profile of each 
protein in normal mucosa versus tumour tissues was analysed using Mann Whitney U test.  
There was a significant increase in the intensity of immunostaining of CIDEA (p<0.001), 
ELOVL5 (p<0.001) and UCP1 (p<0.001) in primary tumour compared to normal colonic 
mucosa.  Whereas a decrease in the expression of ELOVL3 (p=0.020) was observed in 
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colorectal tumours compared to normal colorectal epithelium. The immunoreactivity for each 
protein was exclusively localised to the cell cytoplasm and no intra-tumour heterogeneity was 
observed (Supplementary Figure S8).   
 The frequency distribution of immunostaining intensities was also evaluated for each 
protein in the discovery and validation cohorts (Figure 1 and Table 2).  The majority of 
tumour tissues showed moderate and strong CIDEA staining while only 11% and 16% of 
tumours in the discovery and validation cohort respectively were CIDEA negative.  Similar 
expression profiles were observed for ELOVL3 and ELOVL5 as both showed moderate and 
strong staining in the majority of tumour samples.  As for UCP1, the majority of tumours 
showed weak immunostaining in both cohorts, while 34% and 41% were negatively stained 
in the discovery set and the validation set respectively.  
When comparing the expression profiles for each protein between the two cohorts, no 
significant difference was observed for CIDEA, ELOVL3 and UCP1 (Table 2).  There was 
significant variation (χ2=12.868, p=0.005) in the expression profile of ELOVL5 between the 
discovery and validation cohorts and the main difference was between the proportion of 
moderate and strong immunostaining. 
 
Relationship of brown fat protein expression with clinico-pathological parameters 
 The relationships between the pathological parameters and the expression of each 
protein were evaluated in the discovery and the validation cohorts (Supplementary Table S5).  
CIDEA showed significant association only with lymph node stage in both the discovery and 
validation cohorts.  The expression of ELOVL3 was significantly associated with MMR 
protein status, extramural venous invasion and UICC stage in both cohorts.  The most robust 
relationships were observed in relation to UCP1 which was significantly associated with 
tumour stage, lymph node stage, UICC stage and overall risk group in each cohort 
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(Supplementary Tables S5 and S6).  The expression of UCP1 significantly decreased as 
tumour stage increased from stage I to stage III (Supplementary Figure S9).   
 
Survival analysis 
Discovery cohort 
 Different cut-off points of the immunostaining scores were used to investigate the 
association between the expression of protein targets and overall survival in the discovery 
cohort.  Significant associations were observed between overall survival and the expression 
of CIDEA and UCP1 (Table 3).   
UCP1 showed the most significant and robust association with survival following the 
dichotomisation of UCP1 staining categories into positive versus negative staining (Figure 2).  
Expression of UCP1 was significantly associated with better survival (HR=0.615, 
95%CI=0.416-0.909, χ2=6.119, p=0.013).  Patients with tumours not expressing UCP1 
(n=90) had a poorer survival with a median survival of 110 months (95%CI=26-193 months) 
compared to a median survival of 114 months (95%CI=95-132 months) for patients with 
tumours expressing UCP1 (n=174).   
The expression of CIDEA was significantly associated with survival when CIDEA 
expression was compared to absent CIDEA expression (HR=0.286, 95%CI=0.138-0.593, 
χ2 =12.945, p<0.001; Supplementary Figure S10).   
 There was no significant association between ELOVL3 or ELOVL5 and survival in 
the discovery cohort (Table 3). 
 
Validation cohort 
Consistent with the result in the discovery cohort, there was also a significant 
association between UCP1 and survival (HR=0.629, 95%CI=0.480-0.825, χ2=11.558, 
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p=0.001; Figure 2).  Patients with tumours not expressing UCP1 (n=214) had a poorer 
survival with a median survival of 75 months (95%CI=65-85 months) compared to a median 
survival of 131 months (95%CI undefined) for patients with tumours expressing UCP1 
(n=303).   
Multivariate analysis was also performed in the validation cohort to determine 
whether UCP1 was prognostically independent of clinically established parameters (Table 4 
and Supplementary Table S7).  The expression of UCP1, stratified as negative versus 
positive, was significantly associated with survival independent of the main prognostic 
factors.  Multivariate analysis was also performed to determine whether UCP1 was 
prognostically independent of parameters that would be available at the time of biopsy 
(Supplementary Table S8).  This analysis showed that the expression of UCP1 was also 
strongly prognostic in a scenario where only pre-surgical resection parameters are available 
(p=0.001).   
There was no significant association between the expression of CIDEA and survival 
in the validation cohort. 
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Discussion 
Colorectal cancer is a common type of cancer and one of the major contributors to 
cancer-related mortalities.1,2  The survival rate of colorectal cancer patients is still relatively 
poor despite recent advances in understating the molecular pathology of this type of tumour.2  
Better understanding of novel molecular pathways underpinning colorectal cancer 
progression is necessary to improve the current survival rates. 
The expression of brown fat phenotype has been observed in prostate, lung and breast 
carcinoma and has been implicated in tumour growth.15,16,28  However, the expression of this 
phenotype in colorectal carcinoma and its association with survival among other clinico-
pathological parameters has not yet been investigated.  
In this study, a peptide immunogen approach was used to develop a panel of 
monoclonal antibodies to brown fat-associated proteins CIDEA and ELOVL3, ELOVL5 and 
UCP1.  The antibodies were validated by immunoblotting and then their immunoreactivity 
was evaluated by immunohistochemistry on a multi-tissue microarray.  The immunostaining 
profiles of CIDEA, ELOVL3 and ELOVL5 in the multi-tissue microarray were consistent 
with the knowledge on the mRNA expression of these genes.29,30  The expression of UCP1 in 
normal endocrine pancreas31 and hibernoma32 was also in agreement with the current limited 
knowledge of the expression of this protein.  
After validating the antibodies on the multi-tissue microarray, they were used to 
profile the expression pattern of each protein on well-characterised discovery and validation 
cohorts of colorectal cancers.  Statistical and descriptive analysis of the clinico-pathological 
characteristics of patients and their association with survival showed that both cohorts were 
comparable and valid for the purpose of this study.  
The results showed that there was a significant increase in the expression of brown 
fat-associated proteins CIDEA, ELOVL5 and UCP1 in colorectal tumour compared to normal 
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colonic mucosa.  The detection of brown fat-like phenotype, characterised by UCP1 
expression, in colorectal cancer could be the result of the unlimited plasticity of cancer stem 
cells, which can differentiate into multiple linages with various phenotypes based on genetic 
mutations and microenvironmental factors.15,16  The origin of cancer stem cells could be 
normal stem cells, resident in the colonic crypts or recruited from bone marrow by 
inflammatory mediators, that may have been transformed as a result of oncogenic 
mutations.33,34  Cancer stem cells could also originate from normal epithelial cells as a result 
of epithelial-mesenchymal transition which is a process implicated in colorectal cancer.35  
The prognostic value of each protein was firstly assessed by investigating associations 
between the expression of proteins and overall survival in the discovery cohort, and then the 
results were confirmed in the validation cohort.  This revealed there was a significant 
association between the expression of UCP1 and better survival in colorectal cancer in both 
the discovery and validation cohorts.  Using a robust cut-off point (positive versus negative), 
a considerable difference in median survival (56 months) was observed between the poor 
prognosis group (i.e. patients with tumours not expressing UCP1) and the good prognosis 
patient group (i.e. patients with tumours expressing UCP1).  More importantly, the prognostic 
impact of UCP1 was significantly independent of established prognostic parameters.  
Therefore, the assessment of UCP1 by immunohistochemistry could be a valuable addition to 
current prognostic parameters in clinical practice as positive UCP1 immunostaining versus 
negative is a robust cut-off point which could be evaluated by straightforward 
immunohistochemical analysis on fixed tumour tissue. However, potential limitations of this 
study are the size of the discovery cohort and the reliance on one technology for validation 
(i.e. immunohistochemistry). In addition, there is still a need for additional validation of the 
prognostic impact of UCP1. It may also be worthwhile evaluating UCP1 in serum samples 
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from CRC patients. More importantly, the biology of UCP1 and associated pathways need to 
be investigated in relation to cancer development and growth. 
The expression of UCP1 was also independently prognostic in multivariate analysis 
using parameters that would be available at the biopsy stage.  Therefore, UCP1 could also be 
a useful biopsy-biomarker since it would provide prognostic information at an early stage 
prior to tumour resection.  This is particularly relevant as neoadjuvant therapy followed by 
active surveillance is a treatment strategy which is likely to be increasingly used.36   
The positive impact of UCP1 on survival may be explained by the role of UCP1 in the 
mitochondrion.  Functional mitochondria is essential for metabolism, oxidative stress, 
apoptosis, signalling and proliferation.37  Overexpressing UCP1 in breast cancer cells line 
resulted in mitochondrial dysfunction that lead to a significant reduction in tumour growth.38  
Tumour growth was inhibited by mitochondrial-induced catabolism in cancer cells expressing 
UCP1.38   
In another study, the overexpression of uncoupling protein 3, a close family member 
of UCP1, reduced the growth of skin cancer in mice as a result of constitutive oxidation of 
substrates and nutrients that are essential for maintaining tumour growth, without 
simultaneous ATP production.39  Furthermore, mitochondrial uncoupling blocked the 
activation of AKT serine/threonine kinase 1 (AKT) in mice thereby limiting proliferation and 
tumorigenesis.39  Therefore, UCP1 could inhibit tumour growth by modulating and disrupting 
the metabolism of mitochondrion, which would lead to loss of nutrients, catabolism, 
disturbance of the cellular membrane and AKT inhibition (Supplementary Figure S11). 
Dysregulated energy metabolism has been accepted as a hallmark of carcinogenesis, where 
tumour cells manipulate different metabolic pathways to sustain their growth.40 This could 
also be consistent with the consensus molecular subtype 3 (CMS3) of colorectal cancer where 
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multiple metabolic pathways are prominent.41 However, there is still a need to evaluate the 
impact of UCP1 expression on mitochondrial metabolism in colorectal adenocarcinoma. 
 Another previous study by Zhau et al15 also showed that proliferation was slower and 
apoptosis was higher in a prostate cancer cell line as a result of differentiation of cancer stem 
cells to cancer cells expressing UCP1.  The expression of UCP1 might be associated with the 
differentiation of cancer stem cells to mature cancer cells that are more vulnerable to 
apoptosis.15  
However, Singh and co-workers reported that tumour development and growth might 
be improved by the expression of UCP1 in a xenograft model of breast cancer.16  The 
development of xenograft was inhibited after injecting mice with UCP1-negative cancer cells.  
Therefore, further investigation of the impact of UCP1 on tumour development and growth is 
still required. 
 In summary, this study has shown that UCP1, which is normally not present in normal 
colonic mucosa, is expressed in colorectal cancer and is significantly and independently 
associated with survival.  This means the assessment of UCP1 in colorectal cancer could be a 
useful addition to current prognostic parameters used in clinical practice.  Furthermore, UCP1 
is an actionable protein and therefore is a valid target for therapeutic intervention. 
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Table 1.  Clinico-pathological characteristics of all patients, their tumours and the relationship of each variable with overall survival in the discovery and 
validation cohorts. 
 
Clinico-pathological characteristic Discovery cohort (n=274) Validation cohort (n=549) 
Percentage 
(number) 
Relationship with survival Percentage 
(number) 
Relationship with survival 
Gender Male 52.9 (145) χ2=0.137, p=0.711 51.9 (285) χ2=0.000, p=0.989 
Female 47.1 (129) 48.1 (264) 
Age <70 43.4 (119) χ2=3.045, p=0.065 45.5 (249) χ2=26.095, p<0.001 
≥70 56.6 (155) 54.6 (300) 
Bowel screening programme 
detected 
Yes 12 (33) χ2=10.520, p=0.001 9.1 (50) χ2=6.721, p=0.010 
No 88 (241) 90.9 (499) 
Tumour site 
Proximal colon 34.3 (94) Proximal vs distal, χ2=3.040, p=0.081 40.2 (221) Proximal vs distal, χ2=6.392, p=0.011 
Distal colon 46 (126) Distal vs rectal, χ2=0.003, p=0.953 40.7 (223) Distal vs rectal, χ2=1.075, p=0.300 
Rectum 19.7 (54) Colon vs rectum, χ2=0.586, p=0.444 19.1 (105) Colon vs rectum, χ2=0.002, p=0.692 
Tumour differentiation 
G1/G2, well/moderate 90.9 (249) χ2=1.932, p=0.165 92.3 (507) χ2=1.149, p=0.284 
G3, poor 9.1 (25) 7.7 (42) 
Extramural venous invasion V1, present 23.4 (64) χ2=62.876, p<0.001 20.4 (112) χ2=61.508, p<0.001 
V0, absent 76.6 (210) 79.6 (437) 
Mismatch repair protein status Deficient 23.1 (62) χ2=0.402, p=0.526 12.7 (68) χ2=2.933, p=0.087 
Proficient 76.9 (206) 87.3 (468) 
pT category 
pT1 5.8 (16) pT1 vs pT2, χ2=1.990, p=0.158 4.5 (25) pT1 vs pT2, χ2=1.176, p=0.278 
pT2 12.8 (35) pT2 vs pT3, χ2=6.950, p=0.008 17.5 (96) pT2 vs pT3, χ2=16.205, p<0.001 
pT3 63.5 (174) pT3 vs pT4, χ2=33.960, p<0.001 63.9 (351) pT3 vs pT4, χ2=14.681, p<0.001 
pT4 17.9 (49)  14.1 (77)  
pN category 
pN0 58 (159) pN0 vs pN1, χ2=25.234, p<0.001 58 (320) pN0 vs pN1, χ2=35.321, p<0.001 
pN1 26 (70) pN1 vs pN2, χ2=10.984, p=0.001 26 (141) pN1 vs pN2, χ2=11.300, p=0.001 
pN2 16 (45)  16 (88)  
UICC stage 
I  16.4 (45) 
 
I vs II, χ2=3.599, p=0.058 18.2 (100) I vs II, χ2=3.269, p=0.071 
II  41.6 (114) II vs III, χ2=35.045, p<0.001 40.1 (220) II vs III, χ2=45.613, p<0.001 
III  42 (115)  41.7 (229)  
Low risk* vs high risk  Low risk 46.4 (127) Low risk vs high risk, χ
2=45.973, 
p<0.001 
45.5 (250) Low risk vs high risk, χ2=60.249, 
p<0.001 High risk 53.6 (147) 54.5 (299) 
Significant values are highlighted in bold.  *Low risk (pT1-pT3 and G1 or G2 and V0, pN0): high risk (pT4 or G3 or V1 and pN0 or any pN1 or pN2 tumour)
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Table 2.  Comparison of the expression profile of each protein in tumour samples in the discovery and the validation cohorts. 
 
Expression 
category 
CIDEA ELOVL3 ELOVL5 UCP1 
Discovery Validation Discovery Validation Discovery Validation Discovery Validation 
Negative 11 (4%) 16 (3%) 22 (8%) 28 (5%) 10 (4%) 17 (3%) 90 (34%) 214 (41%) 
Weak 42 (16%) 107 (21%) 50 (19%) 117 (22%) 53 (20%) 111 (21%) 129 (49%) 229 (44%) 
Moderate 81 (32%) 171(33%) 83 (32%) 141 (26%) 73 (28%) 206 (39%) 32 (12%) 54 (11%) 
Strong 124 (48%) 222 (43%) 108 (41%) 249 (47%) 128 (48%) 193 (37%) 13 (5%) 20 (4%) 
Chi-squared test: 
discovery vs validation 
χ2=3.579, p=0.311 χ2=6.331, p=0.097 χ2=12.868, p=0.005 χ2=4.097, p=0.251 
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Table 3.  The relationship between the expression of each protein and survival in the discovery cohort using different cut-off points for 
the intensity of the immunostaining. 
 
CIDEA 
(n=258) 
Negative=11 (4%)  
Weak=42 (16%)  
Moderate=81 (32%)  
Strong=124 (48%) 
Negative=11 (4%)  
Weak/moderate /strong= 247 
(96%) 
Negative/weak=53 (20%)  
Moderate/strong=205 (80%) 
Strong=134 (48%)  
Negative/weak/moderate=124 (52%) 
χ2=13.385, p=0.004 
 
χ2=12.945, p<0.001 
 
χ2=0.095, p=0.582 χ2=0.193, p=0.660 
ELOVL3 
(n=263) 
Negative=22 (8%)  
Weak= 50 (19%) 
Moderate=83 (32%)  
Strong=108 (41%) 
Negative=22 (8%) 
Weak/moderate/strong=241 (92%) 
Negative/weak=72 (27%) 
Moderate/strong=191 (73%) 
Strong=108 (41%)  
Negative/weak/moderate=155 (59%) 
χ2=5.289, p=0.152 
 
χ2=2.101, p=0.147 
 
χ2=3.313, p=0.069 
 
χ2=3.787, p=0.052 
 
ELVOL5 
(n=264) 
Negative=10 (4%)  
Weak=53 (20%) 
Moderate=73 (28%)  
Strong=128 (48%) 
Negative=10 (4%) 
Weak/moderate/strong=254 (96%) 
Negative/weak=63 (24%) 
Moderate/strong=201 (76%) 
Strong=128 (48%)  
Negative/weak/moderate=136 (52%) 
χ2=3.571, p=0.312 
 
 
χ2=0.751, p=0.386 
 
χ2=0.913, p=0.339 
 
χ2=0.094, p=0.759 
 
UCP1 
(n=264) 
Negative=90 (34%)  
Weak=129 (49%) 
Moderate=32 (12%)  
Strong=13 (5%) 
Negative=90 (34%)  
Weak/moderate/strong=174 (66%) 
Negative/weak=219 (83%) 
Moderate/strong=45 (17%) 
Strong=13 (5%)  
Negative/weak/moderate=251 (95%) 
χ2=8.008, p=0.046 
 
χ2=6.119, p=0.013 
 
χ2=3.216, p=0.073 
 
χ2=0.000, p=0.996 
 
Significant values are highlighted in bold.   
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Table 4.  Multivariate analysis of UCP1, age and risk groups in the validation cohort. 
 
Variable Number of 
deaths/number of 
patients 
Wald value p-value Hazard ratio (95%CI) 
Age at surgery (< 70* vs ≥ 70) < 70 
≥ 70 
79/249 
150/300 
25.184 <0.001 2.075 (1.560-2.760) 
Low risk* vs high risk  Low risk 
High risk 
69/250 
160/299 
46.247 <0.001 2.773 (2.067-3.721) 
UCP1 (negative* vs positive)        Negative 
Positive 
101/214 
112/303 
8.385 0.004 0.669 (0.509-0.878) 
Significant values are highlighted in bold.  *represents the reference group. 
 
 
 
 
 
 
 
30 
 
Figure legends 
 
Figure 1. 
The frequency of negative, weak, moderate and strong immunostaining for CIDEA, 
ELOVL3, ELOVL5 and UCP1 in normal colonic mucosa and colorectal cancers in the 
discovery cohort and in colorectal cancers in the validation cohort. 
 
Figure 2. 
The relationship between the expression of UCP1 and overall survival in the discovery cohort 
(A) and in the validation cohort (B) using positive expression vs negative expression as the 
cut-off point.  
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Materials and methods S1 
 
Histopathological processing of colorectal tissue specimens 
 Resection specimens were received fresh, opened along the anti-mesenteric aspect, 
excluding dissection through the tumour so as to ensure assessment of the serosal aspect of 
the tumour, washed in cold water and then fixed in 10% neutral buffered formalin for at least 
48 hours at room temperature.  Representative tissue blocks were embedded in wax and 
sections were then stained with haematoxylin and eosin for histopathological diagnosis.  
Areas of tissue to be sampled were first identified and marked on the appropriate 
haematoxylin and eosin stained slide by GIM, an expert gastro-intestinal pathologist.   
 
Immunohistochemistry-multi-tissue and colorectal microarrays 
 To dewax the tissue microarrays slides, they were immersed in xylene for 10 minutes.  
The slides were then rehydrated by immersion for 2 minutes in decreasing ethanol 
concentrations.  Antigen retrieval was performed by heating the sections in a microwave 
(800W) for 20 minutes while they are fully immersed in citrate buffer (pH=6).  The slides 
were allowed to cool off and then were incubated for 60 minutes at room temperature with 
primary antibody (culture supernatants).  All primary antibodies were used undiluted except 
for ELOVL3 which was diluted at 1:10 in antibody diluent (Dako).  Then, the sections were 
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washed twice with washing buffer (Dako) and blocked with peroxidase blocking solution 
(Dako) for 7 minutes.  This was followed by further two washes with washing buffer (Dako). 
Peroxidase-polymer labelled goat anti-mouse secondary antibody (Envision™, Dako) was 
then applied for 30 minutes at room temperature.  Thereafter, the slides were washed twice 
with Dako buffer and diaminobenzidine substrate was applied for 7 minutes to reveal sites of 
peroxidase activity.  Finally, the sections were washed in water, immersed in copper sulphate 
for 2 minutes counterstained with haematoxylin for 10 seconds, and placed in Scott’s tap 
water substitute for 2 minutes.  Before being mounted, the tissue sections were dehydrated by 
immersion in increasing ethanol concentrations and xylene.  As a negative control, antibody 
diluent was used to replace the primary monoclonal antibody. 
 
Data analysis and statistics    
  Biomarker targets were first assessed in the discovery cohort by univariate analysis 
using the method of Kaplan-Meier to determine the predictive performance of each 
biomarker.  To comprehensively explore the correlations between intensity of 
immunostaining and survival, the expression of each protein was dichotomised into the 
following categories:   
- Overall: negative vs weak vs moderate vs strong 
- Negative vs positive i.e. negative vs weak, moderate or strong 
- High vs low i.e. negative and weak vs moderate and strong 
- Strong vs the remaining staining categories i.e. negative, weak and moderate vs 
 strong 
 The following criterion were evaluated to determine the prognostic performance of 
each protein before they were considered suitable targets for validation; the ability to 
distinguish between good prognosis and poor prognosis groups (Kaplan-Meier plot), survival 
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variations between good and poor prognosis groups (median survival), chi-square value, p-
value, hazard ratio with 95% confidence intervals, the number of patients in each prognostic 
group and robustness of the cut-off point.  For each protein that showed significant 
association with survival, the above analysis was repeated in the validation cohort.  Each 
protein that was associated with survival in univariate analysis was added to a multivariate 
model in the validation cohort to determine if any protein was independently prognostic. 
SPSS does not calculate a confidence interval if the cumulative survival of patients is more 
than 50%. Therefore, in those circumstances the confidence interval has been reported as 
undefined. 
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Table S1.  List of online bioinformatics tools, their functions and web addresses. 
Name Aim Web address 
Basic Local 
Alignment Search 
Tool (BLAST) 
Determination of the 
specificity of the immunogen 
peptide  
(http://web.expasy.org/blast/)   and/or 
https://blast.ncbi.nlm.nih.gov/Blast.cgi  
B-cell epitope 
prediction tool  
Prediction of accessible, 
hydrophilic, antigenic and 
flexible amino acid sequences 
(http://tools.immuneepitope.org/tools/b
cell/iedb_input 
PHYRE2 Protein 
Fold Recognition 
Server 
Prediction of the tertiary 
structure of proteins 
http://www.sbg.bio.ic.ac.uk/phyre2/ht
ml/page.cgi?id=index 
Protter Prediction of the secondary 
structure of proteins  
http://wlab.ethz.ch/protter/start 
 
Clustal Omega Identification of regions of 
high amino acids diversity by 
multiple alignments 
http://www.ebi.ac.uk/Tools/msa/clustal
o/ 
List of online bioinformatics tools that were used for predicting amino acids sequence that is 
suitable as immunogen peptide.   
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Table S2.  Peptide sequences used as immunogens to generate monoclonal antibodies. 
 
 
Hybridoma clone Peptide sequence 
N-terminus – C-terminus 
Peptide location 
CIDEA V62P1E3*B10 QAKGRFTCG 211-219 
ELOVL3 V61 P2B3*D10 QPYNFELSK 16-24 
ELOVL5  Z88 NNVKPRKLR  289-297 
UCP1 Vab12 P4B12*A12 GIKPRYTGTY 149-158 
 
 
 
 
 
.
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Table S3.  The numbers of normal and tumour tissue samples in the multi-tissue microarray.   
Tissue type Normal tissue (n=51) Tumour tissue (n=68) 
Breast 4 4 
Oesophagus 4 4 
Stomach 4 4 
Colon  4 4 
Liver 4 4 
Pancreas 4 4 
Prostate 4 4 
Kidney 4 4 
Bladder tumour - 4 
Lymph node/lymphoma 1 3 
Sarcoma/GIST 
 
- 8 
Adrenal-normal 4 - 
Thyroid  2 2 
Ovary-tumour - 4 
Endometrium-tumour 
 
- 4 
Normal skin/melanoma 2 3 
Lung 
 
4 4 
Testis 2 4 
Placenta 4 - 
The multi-tissue microarray was developed by the NHS Grampian Biorepository, Aberdeen, UK. 
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Table S4. Comparison of the clinico-pathological characteristics of the discovery and validation cohorts. 
Clinico-pathological characteristic Discovery cohort 
 
Validation cohort 
 
Chi-squared value: discovery vs 
validation 
 
 
Percentage (number) Percentage (number) 
Gender Male 52.9 (145) 51.9 (285) p=0.785 
Female 47.1 (129) 48.1 (264) 
Age <70 43.4 (119) 45.5 (249) p=0.601 
≥70 56.6 (155) 54.6 (300) 
Bowel screening programme 
detected 
Yes 12 (33) 9.1 (50) p=0.187 
No 88 (241) 90.9 (499) 
Tumour site Proximal colon 34.3 (94) 40.2 (221) p=0.227 
Distal colon 46 (126) 40.7 (223) 
Rectum 19.7 (54) 19.1 (105) 
Tumour differentiation G1/G2, well/moderate 90.9 (249) 92.3 (507) p=0.466 
G3, poor 9.1 (25) 7.7 (42) 
Extramural venous invasion V1, present 23.4 (64) 20.4 (112) p=0.330 
V0, absent 76.6 (210) 79.6 (437) 
Mismatch repair protein status Deficient 23.1 (62) 12.7 (68) p<0.001 
Proficient 76.9 (206) 87.3 (468) 
pT category pT1 5.8 (16) 4.5 (25) p=0.176 
 pT2 12.8 (35) 17.5 (96) 
pT3 63.5 (174) 63.9 (351) 
pT4 17.9 (49) 14.1 (77) 
pN category pN0 58 (159) 58 (320) p=0.990 
 pN1 26 (70) 26 (141) 
pN2 16 (45) 16 (88) 
UICC stage I  16.4 (45) 18.2 (100) p=0.802 
II  41.6 (114) 40.1 (220) 
III  42 (115) 41.7 (229) 
Low risk vs high risk Low risk 46.4 (127) 45.5 (250) p=0.825 
High risk 53.6 (147) 54.5 (299) 
Significant values are highlighted in bold.  Only the mismatch repair protein status was significantly different between the two cohorts 
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Table S5.  The relationship between clinico-pathological parameters and the expression of each protein categorised as negative versus  
weak versus moderate versus strong. 
 CIDEA ELOVL3 UCP1 
 Discovery Validation Discovery Validation Discovery Validation 
 χ2 p-value χ2 p-value χ2 p-value χ2 p-value χ2 p-value χ2 p-value 
Gender (male vs female) 4.327 0.228 6.892 0.075 10.171 0.017 5.222 0.156 3.558 0.313 5.029 0.170 
Age (< 70 vs ≥ 70) 2.848 0.416 3.427 0.330 0.463 0.927 15.998 0.001 1.442 0.696 4.843 0.184 
Bowel screening programme 
detected (no vs yes) 
3.591 0.309 2.212 0.530 9.926 0.019 3.384 0.336 3.629 0.304 6.735 0.081 
Tumour site  
Proximal vs distal vs rectum 
Colon vs rectum 
 
6.742 
4.039 
 
0.345 
0.257 
 
2.630 
0.154 
 
0.854 
0.985 
 
3.818 
2.390 
 
0.701 
0.495 
 
3.188 
1.776 
 
0.785 
0.620 
 
11.249 
9.357 
 
0.081 
0.025 
 
4.921 
2.881 
 
0.554 
0.410 
Mismatch repair protein status 
(deficient vs proficient) 
16.453 0.001 4.128 0.248 16.143 0.001 20.290 <0.001 14.658 0.002 3.649 0.302 
Tumour differentiation 
(well/moderate vs poor) 
 
5.674 0.129 1.190 0.755 15.936 0.001 1.171 0.760 4.390 0.222 2.748 0.432 
Extramural venous invasion 
(present vs absent) 
7.874 0.049 3.474 0.324 7.909 0.048 10.859 0.013 5.000 0.172 3.952 0.267 
Tumour category (pT1 vs pT2 
vs pT3 vs pT4) 
15.270 0.084 18.408 0.031 12.806 0.172 17.792 0.038 18.989 0.025 18.180 0.033 
Lymph node category (pN0 vs 
pN1 vs pN2) 
16.910 0.010 17.191 0.009 17.709 0.007 2.966 0.813 24.282 <0.001 24.822 <0.001 
UICC stage (I vs II vs III) 10.152 0.118 25.073 <0.001 15.669 0.016 14.546 0.024 32.882 <0.001 30.550 <0.001 
Low risk vs high risk 6.460 0.091 15.496 0.001 10.957 0.012 5.939 0.115 18.744 <0.001 9.921 0.019 
Chi-squared test. Significant values are highlighted in bold. ELOVL5 was not included as there were significant differences in its expression 
profile between the discovery and validation cohorts.  
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Table S6.  The relationship between pathological parameters and the expression of UCP1 when it was categorised as either negative or 
positive in each cohort. 
 Discovery Validation 
χ2 p-value χ2 p-value 
Gender (male vs female) 3.385 0.066 2.791 0.095 
Age (< 70 vs ≥ 70) 0.704 0.401 2.133 0.144 
Bowel screening programme detected (no vs yes) 0.577 0.448 0.430 0.512 
Tumour site  
Proximal colon vs distal colon vs rectum 
Colon vs rectum 
 
6.319 
4.832 
 
0.042 
0.028 
 
2.439 
2.350 
 
0.295 
0.125 
Mismatch repair protein status (deficient vs proficient) 14.406 <0.001 1.737 0.187 
Tumour differentiation (well/moderate vs poor) 
 
3.667 0.056 0.001 0.979 
Extramural venous invasion (present vs absent) 1.677 0.195 1.511 0.219 
Tumour category (pT1 vs pT2 vs pT3 vs pT4) 7.582 0.055 14.203 0.003 
Lymph node category (pN0 vs pN1 vs pN2) 18.199 <0.001 14.325 0.001 
UICC stage (I vs II vs III)  19.185 <0.001 19.659 <0.001 
Low risk vs high risk 12.533 <0.001 6.594 0.010 
Chi-squared test, significant values are highlighted in bold. 
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Table S7.  Multivariate analysis of age, tumour differentiation, EMVI, tumour stage, lymph node stage and UCP1 in the validation 
cohort. 
Variable Number of 
deaths/number 
of patients 
Wald value p-value Hazard ratio (95%CI) 
Age at surgery (< 70* vs ≥ 70) < 70 
 ≥ 70 
79/249 
150/300 
33.143 <0.001 2.380 (1.772-3.197) 
Tumour differentiation (well/moderate* vs poor) Poor 
Well/moderate  
19/42 
210/507 
1.973 0.160 0.664 (0.375-1.176) 
Extramural venous invasion (present vs absent*) Absent  
Present  
 
152/437 
77/112 
17.749 <0.001 1.959 (1.443-2.679) 
Tumour category (pT1 vs pT2*) 
                       (pT2 vs pT3*) 
                       (pT3 vs pT4*)  
pT1 
pT2 
pT3 
pT4 
9/25  
27/96  
149/351  
44/77  
0.979 
6.245 
5.503 
0.323 
0.012 
0.019 
 
0.669 (0.302-1.483) 
0.509 (0.300-0.864) 
0.644 (0.446-0.930) 
Lymph node category (pN0 vs pN1*) 
                               (pN1 vs pN2*) 
pN0 
pN1 
pN2 
97/320  
71/141  
61/88  
41.004 
6.969 
<0.001 
0.008 
0.293 (0.202-0.427) 
0.600 (0.410-0.877) 
UCP1 (negative* vs positive) Negative 
Positive 
101/214 
112/303 
5.059 0.024 0.724 (0.546-0.959) 
Significant values are highlighted in bold. *represents the reference group.  
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Table S8. Multivariate analysis of UCP1 using parameters that would be available with a biopsy in the validation cohort. 
Variable Number of 
deaths/number of 
patients 
Wald value p-value Hazard ratio (95%CI) 
Age (< 70* vs ≥ 70) < 70 
≥ 70 
79/249 
150/300 
20.205 <0.001 1.996 (1.477-2.698) 
Gender (male* vs female) Male 
Female 
118/285 
111/264 
0.000 0.991 0.998 (0.758-1.316) 
Bowel screening programme detected (no vs 
yes*) 
No 
Yes 220/499 9/50 
1.372 0.241 1.510 (0.758-3.011) 
Tumour site (colon vs rectum*) Colon 
Rectum 
177/444 
52/105 
0.567 0.451 0.881 (0.633-1.226) 
Mismatch repair protein status (proficient* vs 
deficient) 
Proficient 
Deficient 188/468 33/68 
1.614 0.204 1.289 (0.871-1.906) 
Tumour differentiation (well/moderate* vs 
poor) 
Poor  
Well/moderate 
19/42 
210/507 0.946 0.331 0.745 (0.411-1.348) 
UCP1 (negative* vs positive) Negative  
Positive 
101/214 
112/303 
11.779 0.001 0.614 (0.464-0.811) 
Significant values are highlighted in bold. *represents the reference group. 
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Figure S1. Sequence alignment of proteins targets and their family members completed by multiple alignment (Clustal Omega) 
(peptides highlighted in yellow are peptides immunogens). 
 
1.1 CIDEA 
SP|Q96AQ7|CIDEC_HUMAN MEYAMKSLSLLYPKSLSRHVSVRTSVVTQQLLSEPSPKAPRARPCRVSTADRSVRKGIMA 60 
SP|O60543|CIDEA_HUMAN MEAA-----RDYAGALIRPLTFMGSQT-KR--VLFTPLMHPARPFRVSNHDRSSRRGVMA 52 
SP|Q9UHD4|CIDEB_HUMAN ----MEYLSALNPSDLLRSVSNISSEFGRR---VWTSAPPPQRPFRVCDHKRTIRKGLTA 53 
                                     * * ::   *   ::     :      ** **.  .*: *:*: * 
SP|Q96AQ7|CIDEC_HUMAN YSLEDLLLKVRDTLMLADKPFFLVLEEDGTTVETEEYFQALAGDTVFMVLQKGQKWQPPS 120 
SP|O60543|CIDEA_HUMAN SSLQELISKTLDALVIATGLVTLVLEEDGTVVDTEEFFQTLGDNTHFMILEKGQKWMPGS 112 
SP|Q9UHD4|CIDEB_HUMAN ATRQELLAKALETLLL-NGVLTLVLEEDGTAVDSEDFFQLLEDDTCLMVLQSGQSWSPTR 112 
                       : ::*: *. ::*::    . ********.*::*::** * .:* :*:*:.**.* *   
SP|Q96AQ7|CIDEC_HUMAN EQGTRHPLSLSHKPAKKIDVARVTFDLYKLNPQDFIGCLNVKATFYDTYSLSYDLHCCGA 180 
SP|O60543|CIDEA_HUMAN QHVP------TCSPPKRSGIARVTFDLYRLNPKDFIGCLNVKATMYEMYSVSYDIRCTGL 166 
SP|Q9UHD4|CIDEB_HUMAN SGVLSYGLG-RERPKHSKDIARFTFDVYKQNPRDLFGSLNVKATFYGLYSMSCDFQGLGP 171 
                      .            * :  .:**.***:*: **:*::*.******:*  **:* *::  *  
SP|Q96AQ7|CIDEC_HUMAN KRIMKEAFRWALFSMQATGHVLLGTSCYLQQLLDATEEGQPPKGKASSLIPTCLKILQ 238 
SP|O60543|CIDEA_HUMAN KGLLRSLLRFLSYSAQVTGQFLIYLGTYMLRVLDDKEERPSLRSQAKGRF-TCG---- 219 
SP|Q9UHD4|CIDEB_HUMAN KKVLRELLRWTSTLLQGLGHMLLGISSTLRHAVEGAEQWQQK-GRLHSY--------- 219 
                      * :::. :*:     *  *:.*:  .  : : ::  *:     .:  .           
 
1.2. ELOVL family 
SP|A1L3X0|ELOV7_HUMAN ------------MAFSDLTSRTVHLYDNWIKDADPRVEDWLLMSSPLP-QTILLGFYVYF 47 
SP|Q9BW60|ELOV1_HUMAN ------------------MEAVVNLYQEVMKHADPRIQGYPLMGSPLL-MTSILLTYVYF 41 
SP|Q9NYP7|ELOV5_HUMAN --------------MEHFDASLSTYFKALLGPRDTRVKGWFLLDNYIP-TFICSVIYLLI 45 
SP|Q9NXB9|ELOV2_HUMAN -----------MEHLKAFDDEINAFLDNMFGPRDSRVRGWFMLDSYLP-TFFLTVMYLLS 48 
SP|Q9GZR5|ELOV4_HUMAN MGLLDSEPGSVLNVVSTALNDTVEFYRWTWSIADKRVENWPLMQSPWP-TLSISTLYLLF 59 
SP|Q9H5J4|ELOV6_HUMAN ------------MNMSV---LTLQEYEFEKQFNEN--EAIQWMQENWKKSFLFSALYAAF 43 
SP|Q9HB03|ELOV3_HUMAN --------MVTAMNVSHEVNQLFQPYNFEL---SK--DMRPFFEEYWATSFPIALIYLVL 47 
                                                       .        : .           *    
SP|A1L3X0|ELOV7_HUMAN VTSLGPKLMENRKPFELKKAMITYNFFIVLFSVY--------MCYEFVMSGWGIGYSFRC 99 
SP|Q9BW60|ELOV1_HUMAN VLSLGPRIMANRKPFQLRGFMIVYNFSLVALSLY--------IVYEFLMSGWLSTYTWRC 93 
SP|Q9NYP7|ELOV5_HUMAN V-WLGPKYMRNKQPFSCRGILVVYNLGLTLLSLY--------MFCELVTGVWEGKYNFFC 96 
SP|Q9NXB9|ELOV2_HUMAN I-WLGNKYMKNRPALSLRGILTLYNLGITLLSAY--------MLAELILSTWEGGYNLQC 99 
SP|Q9GZR5|ELOV4_HUMAN V-WLGPKWMKDREPFQMRLVLIIYNFGMVLLNLF--------IFRELFMGSYNAGYSYIC 110 
SP|Q9H5J4|ELOV6_HUMAN I-FGGRHLMNKRAKFELRKPLVLWSLTLAVFSIFGALRTGAYMVYILMTKGLKQ---SVC 99 
SP|Q9HB03|ELOV3_HUMAN I-AVGQNYMKERKGFNLQGPLILWSFCLAIFSILGAVRMWGIMGTVLLTGGLKQ---TVC 103 
                      :   * . * .:  :. :  :  :.: :. :.          :   :.           * 
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SP|A1L3X0|ELOV7_HUMAN DIVDYSRSPTALRMARTCWLYYFSKFIELLDTIFFVLRKKNSQVTFLHVFHHTIMPWTWW 159 
SP|Q9BW60|ELOV1_HUMAN DPVDYSNSPEALRMVRVAWLFLFSKFIELMDTVIFILRKKDGQVTFLHVFHHSVLPWSWW 153 
SP|Q9NYP7|ELOV5_HUMAN QGTRT-AGESDMKIIRVLWWYYFSKLIEFMDTFFFILRKNNHQITVLHVYHHASMLNIWW 155 
SP|Q9NXB9|ELOV2_HUMAN QDLTS-AGEADIRVAKVLWWYYFSKSVEFLDTIFFVLRKKTSQITFLHVYHHASMFNIWW 158 
SP|Q9GZR5|ELOV4_HUMAN QSVDYSNNVHEVRIAAALWWYFVSKGVEYLDTVFFILRKKNNQVSFLHVYHHCTMFTLWW 170 
SP|Q9H5J4|ELOV6_HUMAN DQGFYNGPV----SKFWAYAFVLSKAPELGDTIFIILRKQ--KLIFLHWYHHITVLLYSW 153 
SP|Q9HB03|ELOV3_HUMAN FINFIDNST----VKFWSWVFLLSKVIELGDTAFIILRKR--PLIFIHWYHHSTVLVYTS 157 
                                        : : .**  *  ** :::***.   : .:* :**  :      
SP|A1L3X0|ELOV7_HUMAN FGVKFAAGGLGTFHALLNTAVHVVMYSYYGLSALGPAYQKYLWWKKYLTSLQLVQFVIVA 219 
SP|Q9BW60|ELOV1_HUMAN WGVKIAPGGMGSFHAMINSSVHVIMYLYYGLSAFGPVAQPYLWWKKHMTAIQLIQFVLVS 213 
SP|Q9NYP7|ELOV5_HUMAN FVMNWVPCGHSYFGATLNSFIHVLMYSYYGLSSV-PSMRPYLWWKKYITQGQLLQFVLTI 214 
SP|Q9NXB9|ELOV2_HUMAN CVLNWIPCGQSFFGPTLNSFIHILMYSYYGLSVF-PSMHKYLWWKKYLTQAQLVQFVLTI 217 
SP|Q9GZR5|ELOV4_HUMAN IGIKWVAGGQAFFGAQLNSFIHVIMYSYYGLTAFGPWIQKYLWWKRYLTMLQLIQFHVTI 230 
SP|Q9H5J4|ELOV6_HUMAN YSYKDMVAGGGWF-MTMNYGVHAVMYSYYALRAAGFRVSR--KFAMFITLSQITQMLMGC 210 
SP|Q9HB03|ELOV3_HUMAN FGYKNKVPAGGWF-VTMNFGVHAIMYTYYTLKAANVKPPK--MLPMLITSLQILQMFVGA 214 
                         :    . . *   :*  :* :** ** *                :*  *: *: :   
SP|A1L3X0|ELOV7_HUMAN IHIS---QFFFMEDCKYQFPVFAC-IIMSYSFMFLLLFLHFWYRAYTKGQRLPKTV---- 271 
SP|Q9BW60|ELOV1_HUMAN LHIS---QYYFMSSCNYQYPVIIH-LIWMYGTIFFMLFSNFWYHSYTKGKRLPRAL---- 265 
SP|Q9NYP7|ELOV5_HUMAN IQTS---C-GVIWPCTF--PLGWLYFQIGYMISLIALFTNFYIQTYNKKGASRRKDHLKD 268 
SP|Q9NXB9|ELOV2_HUMAN THTM---S-AVVKPCGF--PFGCLIFQSSYMLTLVILFLNFYVQTYRKKPMKKDMQEPP- 270 
SP|Q9GZR5|ELOV4_HUMAN GHTA---L-SLYTDCPF--PKWMHWALIAYAISFIFLFLNFYIRTYKEPKKPKAGKTA-- 282 
SP|Q9H5J4|ELOV6_HUMAN VVNYLVFCWMQHDQCHSHFQN-IFWSSLMY-LSYLVLFCHFFFEAYIGKMRKTTKAE--- 265 
SP|Q9HB03|ELOV3_HUMAN IVSILTYIWRQDQGCHTTMEH-LFWSFILY-MTYFILFAHFFCQTYIRPKVKAKTKSQ-- 270 
                                    *              *    . ** .*: .:*               
SP|A1L3X0|ELOV7_HUMAN -KNG-TCKNKDN--------------------- 281 
SP|Q9BW60|ELOV1_HUMAN -QQN-GAPGIAKVKAN----------------- 279 
SP|Q9NYP7|ELOV5_HUMAN HQNGSMAAVNGHTNSFSPLENNVKPRK--LRKD 299 
SP|Q9NXB9|ELOV2_HUMAN --AG-KEVKNGFSKAYFTAANGVMNKK--AQ-- 296 
SP|Q9GZR5|ELOV4_HUMAN -MNGISANGVSKSEKQLMIENGKKQKNGKAKGD 314 
SP|Q9H5J4|ELOV6_HUMAN --------------------------------- 
SP|Q9HB03|ELOV3_HUMAN --------------------------------- 
 
1.3. UCP1 
SP|O95258|UCP5_HUMAN MGIFPGIILIFLRVKFATAAVIVSGHQKSTTVSHEMSGLNWKPFVYGGLASIVAEFGTFP 60 
SP|P55851|UCP2_HUMAN ----------------------MVG-----FKATDVPPTATVKFLGAGTAACIADLITFP 33 
SP|P25874|UCP1_HUMAN ----------------------MGG-----LTASDVHPTLGVQLFSAGIAACLADVITFP 33 
SP|P55916|UCP3_HUMAN ----------------------MVG-----LKPSDVPPTMAVKFLGAGTAACFADLVTFP 33 
SP|O95847|UCP4_HUMAN --------------------MSVP-EEEERLLPLTQRWPRASKFLLSGCAATVAELATFP 39 
                                           :                    :. .* *: .*:. *** 
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SP|O95258|UCP5_HUMAN VDLTKTRLQVQGQSIDARF-----KEIKYRGMFHALFRICKEEGVLALYSGIAPALLRQA 115 
SP|P55851|UCP2_HUMAN LDTAKVRLQIQGESQGPVR---ATASAQYRGVMGTILTMVRTEGPRSLYNGLVAGLQRQM 90 
SP|P25874|UCP1_HUMAN LDTAKVRLQVQGECP-------TSSVIRYKGVLGTITAVVKTEGRMKLYSGLPAGLQRQI 86 
SP|P55916|UCP3_HUMAN LDTAKVRLQIQGENQAV-Q---TARLVQYRGVLGTILTMVRTEGPCSPYNGLVAGLQRQM 89 
SP|O95847|UCP4_HUMAN LDLTKTRLQMQGEAALARLGDGARESAPYRGMVRTALGIIEEEGFLKLWQGVTPAIYRHV 99 
                     :* :*.***:**:               *:*:. :   : . **    :.*:  .: *:  
SP|O95258|UCP5_HUMAN SYGTIKIGIYQSLKRLFVERLEDET--LLINMICGVVSGVISSTIANPTDVLKIRMQAQG 173 
SP|P55851|UCP2_HUMAN SFASVRIGLYDSVKQFYT-KGSEH-ASIGSRLLAGSTTGALAVAVAQPTDVVKVRFQAQA 148 
SP|P25874|UCP1_HUMAN SSASLRIGLYDTVQEFLTAGKETA-PSLGSKILAGLTTGGVAVFIGQPTEVVKVRLQAQS 145 
SP|P55916|UCP3_HUMAN SFASIRIGLYDSVKQVYTPKGADN-SSLTTRILAGCTTGAMAVTCAQPTDVVKVRFQASI 148 
SP|O95847|UCP4_HUMAN VYSGGRMVTYEHLREVVFGKSEDEHYPLWKSVIGGMMAGVIGQFLANPTDLVKVQMQMEG 159 
                       .  ::  *: ::..           :   :: *  :* :.   .:**:::*:::* .  
SP|O95258|UCP5_HUMAN SLFQ-------GSMIGSFIDIYQQEGTRGLWRGVVPTAQRAAIVVGVELPVYDITKKHLI 226 
SP|P55851|UCP2_HUMAN RAGG---GRRYQSTVNAYKTIAREEGFRGLWKGTSPNVARNAIVNCAELVTYDLIKDALL 205 
SP|P25874|UCP1_HUMAN HLHGI--KPRYTGTYNAYRIIATTEGLTGLWKGTTPNLMRSVIINCTELVTYDLMKEAFV 203 
SP|P55916|UCP3_HUMAN HLGPSRSDRKYSGTMDAYRTIAREEGVRGLWKGTLPNIMRNAIVNCAEVVTYDILKEKLL 208 
SP|O95847|UCP4_HUMAN KRKLEGKPLRFRGVHHAFAKILAEGGIRGLWAGWVPNIQRAALVNMGDLTTYDTVKHYLV 219 
                                 .   ::  *    *  *** *  *.  * .::   :: .**  *. :: 
SP|O95258|UCP5_HUMAN LSGMMGDTILTHFVSSFTCGLAGALASNPVDVVRTRMMNQR-AIVGHVDLYKGTVDGILK 285 
SP|P55851|UCP2_HUMAN KANLMTDDLPCHFTSAFGAGFCTTVIASPVDVVKTRYMNSAL------GQYSSAGHCALT 259 
SP|P25874|UCP1_HUMAN KNNILADDVPCHLVSALIAGFCATAMSSPVDVVKTRFINSPP------GQYKSVPNCAMK 257 
SP|P55916|UCP3_HUMAN DYHLLTDNFPCHFVSAFGAGFCATVVASPVDVVKTRYMNSPP------GQYFSPLDCMIK 262 
SP|O95847|UCP4_HUMAN LNTPLEDNIMTHGLSSLCSGLVASILGTPADVIKSRIMNQPRDKQGRGLLYKSSTDCLIQ 279 
                         : * .  *  *:: .*:  :  ..*.**:::* :*.          * .  .  :  
SP|O95258|UCP5_HUMAN MWKHEGFFALYKGFWPNWLRLGPWNIIFFITYEQLKRLQI---------- 325 
SP|P55851|UCP2_HUMAN MLQKEGPRAFYKGFMPSFLRLGSWNVVMFVTYEQLKRALMAACTSREAPF 309 
SP|P25874|UCP1_HUMAN VFTNEGPTAFFKGLVPSFLRLGSWNVIMFVCFEQLKRELSKSRQTMDCAT 307 
SP|P55916|UCP3_HUMAN MVAQEGPTAFYKGFTPSFLRLGSWNVVMFVTYEQLKRALMKVQMLRESPF 312 
SP|O95847|UCP4_HUMAN AVQGEGFMSLYKGFLPSWLRMTPWSMVFWLTYEKIREMSGVSPF------ 323 
                         **  :::**: *.:**:  *.::::: :*:::. 
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Figure S2. The predicted secondary and tertiary structure of CIDEA. 
 
 
 
A. The secondary structure of CIDEA was predicted by Protter software.1  Encircled sequence was selected for immunisation to generate anti-
CIDEA antibody.  B. The tertiary structure of CIDEA predicted by Protein Fold Recognition Server PHYRE2.2  The tertiary structure of the 
region from which the peptide was selected was not predicted since only 121 residues (55% of sequence) have been modelled with 100.0% 
confidence).  Therefore, peptide was selected from the C-terminus region which is often highly diversified and accessible. 
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Figure S3. The predicted secondary of ELOVL3 and ELOVL5.                                                                                                                                     
 
 
The secondary structures of ELOVL3 (A), ELOVL5 (B) were predicted by Protter software.1  Encircled sequences were selected for 
immunisation to generate the corresponding antibody.  The tertiary structure was not possible to predict since the prediction software could not 
identify regions with detectable homology to known structures.  Considering there are several transmembrane regions in both enzymes, the 
selection of peptides was limited to the remaining regions given they are not conserved. 
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Figure S4. The predicted secondary and tertiary structure of UCP1. 
 
A. The secondary structure of UCP1 predicted by Protter software. 1  Short sequence (10 amino acids) was selected for immunisation to generate 
anti-UCP1 antibody.  B. The tertiary structure of UCP1 predicted by Protein Fold Recognition Server PHYRE2. 2  Colour rainbow (red to blue) 
mirror the protein sequence from C-terminal to N-terminal (291 residues (95% of sequence) have been modelled with 100.0% confidence).  The 
peptide selected for anti-UCP1 antibody lies within an exposed, flexible and accessible region.  The peptide sequence is commercially sensitive 
and is held for proprietary reasons.
18 
 
Figure S5. Photomicrographs of representative cores showing intensity scale of negative, weak, moderate and strong immunostaining of 
UCP1 in colorectal cancer. 
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Figure S6. Immunoblots of CIDEA (24.6 kDa), ELOVL3 (31.5 kDa), ELVOL5 (35.2 kDa), and UCP1 (33 kDa) monoclonal antibodies. 
The left-hand lane (+) of each panel contains five micrograms of cell lysate (HEK293) overexpression the relevant protein.  The right-hand lane 
(-) of each panel contains five micrograms of empty vector transfected control cell lysate (HEK293). To overexpress each protein, HEK293 cells 
had been transiently transfected using full length reading frame cDNA plasmid of the corresponding target (Novus Biologicals, Oxfordshire, UK 
and OriGene Technologies Rockville, USA). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      CIDEA   ELOVL3   ELOVL5     UCP1     
    +      -       +      -        +      -         +      -                  
49 kDa 
38 kDa 
28 kDa 
18 kDa 
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Figure S7. Photomicrographs of UCP1 in hibernoma and endocrine pancreas 
 
 
 
There is strong immunoreactivity for UCP1 in hibernoma (brown fat tumour) and the islets of 
Langerhans of the pancreas (endocrine pancreas).  
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Figure S8. Photomicrographs of CIDEA, ELOVL3, ELOVL5 and UCP1 in normal 
colonic mucosa and primary colorectal cancer. 
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Figure S9. The frequency of positive and negative immunostaining of UCP1 in individual colorectal cancer stages (stage I vs stage II vs 
stage III) in the discovery and validation cohorts. 
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Figure S10. The relationship between the expression of CIDEA categorised as negative vs positive, and survival in the discovery cohort 
(A) and in the validation cohort (B). 
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Figure S11.  A schematic pathway demonstrating the impact of UCP1 expression in colorectal cancer.  The expression of UCP1 in the 
epithelial compartment of colorectal carcinoma inhibits tumour growth and increases apoptosis.  This is translated into better prognosis 
compared to UCP1-negative tumours.   
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